ENDPOINTS

Pfizer vet William Pao’s next venture; Sanofi’s computa...

William Pao, a longtime R&D leader at Roche who briefly held the chief developme...

Trump’s science crackdown hits rare disease medicine: ‘...

Jill Wood had pinned her hopes on a little-known federal program to fund her son...

Lilly joins molecular glue field with Magnet deal worth...

Another day, another molecular glue deal in the biopharma world. This time a...

HHS’ vaccine injury panel in limbo after monthlong meet...

More than a month after its most recent scheduled meeting was postponed, a panel...

CDC investigating hospitalizations after chikungunya va...

The CDC is looking into a handful of hospitalization cases after people got Ixch...

HHS’ vaccine injury panel in limbo after month-long mee...

More than a month after its most recent scheduled meeting was postponed, a panel...

Pharma-backed Mission Therapeutics stops preclinical op...

Clinical-stage biotech Mission Therapeutics is closing its preclinical laborator...

Drug policy veteran at CMS to depart on Friday

John Coster, CMS' senior technical advisor for the Medicare drug rebate and nego...

Verve is latest gene editing company to suffer setback,...

Verve Therapeutics has not escaped the doom that seems to be engulfing the gene ...

OpenAI meets cancer care

Most healthcare organizations have been using AI for decidedly unglamorous tasks...

Verve is latest gene editing company to suffer setback ...

Verve Therapeutics has not escaped the doom that seems to be engulfing the gene ...

Teladoc reports $1B net loss as it works to turn around...

Teladoc wrapped up its financial year with a $1 billion net loss and disappointi...

Hansoh ends collaboration with Silence; Vir hunts for H...

Plus, news about Alopexx, Medigene, EpimAb and Belite Bio: Hansoh backs out ...

Bayer CEO Bill Anderson previews 2025 turnaround plans

Something changed for Bill Anderson when he turned 50. He was ascending the rank...

Merck mulls new site in Delaware; Granules India buys p...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential ne...

Kallyope quietly reports Phase 2 obesity data, begins m...

Kallyope, a New York City biotech that has raised about $480 million over the pa...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.